High Point Pharmaceuticals, LLC

Transtech Pharma, Inc.

Tan Ren

Adnan M M Mjalli

Robert Carl Andrews

Mohan Rao

Devi Reddy Gohimukkula

David R Jones

Jeff Jiqun Zhu

Bapu Reddy Gaddam

Guoxiang Huang

Rongyuan Xie

Dharma Rao Polisetti

Stephen Thomas Davis

Ramesh Gopalaswamy

Muralidhar Bondlela

Anitha Hari

Raju Bore Gowda

William Kenneth Banner

Ravindra Reddy Yarragunta

Hassan El Abdellaoui

Pingzhen Wang

Devi Reddy Gohimmukkula

Soumya P Sahoo

Suvi Simila

Adnan MM Mjalli

David Jones

The present invention is directed to benzazole compounds that inhibit &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors

Benzazole derivatives, compositions, and methods of use as &#x3b2;-secretase inhibitors

The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.

Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as &#x3b2;-secretase inhibitors

The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.

Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors

Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.

Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use

This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.

Heteroaryl-fused nitrogen heterocycles as therapeutic agents

Growing community of inventors

Colfax, NC, United States of America

Tan Ren